BIVDA Press Releases

15Jan

BIVDA response to Parliament’s vote on the Brexit deal

Today the House of Commons voted down the EU withdrawal agreement and the framework for the future relationship.

Doris-Ann Williams, BIVDA’s Chief Executive, commented: “Today’s vote casts a shadow of uncertainty over the UK’s future relationship with the EU. The IVD industry remains anxious about access for patients to essential diagnostic tests if there is no transition period after 29 March. We therefore call for positive steps to be taken in these testing times and urge Government and policy makers to provide clarity and create sufficient space for our sector so that it is able to meet the significant challenge of ensuring the supply of essential diagnostics tests to patients through 2019.”

For a copy of BIVDA's position paper on Brexit, click here.

Related

BIVDA Launches IVD Value Story

The British In Vitro Diagnostics Association (BIVDA) has today (25 October) launched its new report ...

Read More >

BIVDA, ABPI and CRUK release briefing on new arrangements for commissioning and funding of six molecular diagnostic tests for cancer

BIVDA, ABPI and CRUK have released a stakeholder briefing to clarify the new arrangements for commis...

Read More >

BIVDA responds to the final report of the Accelerated Access Review

Doris-Ann Williams MBE, Chief Executive of BIVDA, has responded to the publication of the final repo...

Read More >

NICE launches HealthTech Connect

NICE has launched HealthTech Connect, an online system for identifying and supporting health technol...

Read More >

BIVDA comment on Withdrawal Agreement and political declaration

Doris-Ann Williams, Chief Executive of BIVDA, comments on the announcement of the Withdrawal Agreeme...

Read More >

BIVDA response to the Secretary of State for Health and Social Care's vision for prevention

Today the Secretary of State for Health and Social Care, Matt Hancock MP, has announced his vision f...

Read More >